Concepedia

Kelly L. Lancaster

KL

4

Publications

143

Citations

4

H-Index

2022

Active since

Affiliations

Mersana Therapeutics (United States)(Current)

Kelly L. Lancaster is an author at Mersana Therapeutics (United States) specializing in tumor biology, tumor immunology, and tumor immunity.

ORCID

Top concepts

Publications per year

2022–2025

4

Publications

4

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James et al. · Nature Communications · 2024 · 55 citations · Full text

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid et al. · Journal of Medicinal Chemistry · 2023 · 44 citations · Full text

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2022 · 24 citations

, , +22

XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster et al. · Clinical Cancer Research · 2025 · 20 citations · Full text

Rows per page

1–4 of 4